PACB News and Press, Pacific Biosciences of California Inc. From 03/30/22

Baker Brothers’ 13F portfolio value decreased from $22.77B to $20.55B this quarter. Incyte and Legend Biotech stakes were increased this quarter. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almost ~63% of the portfolio. For f...

GNOM lacks efficient portfolio reshuffling and may not be able to gain from higher alpha-producing stocks in the near future. Despite being a ‘Genomic Revolution’ fund, it lacks focus, and invested heavily on large cap diverse biotechnology companies. Better ‘...

Company Announces New European Headquarters to Serve Growing Customer Demand in Europe, Middle East and Africa Region Also Announces First Commercial Services Provider in Europe MENLO PARK, Calif., March 23, 2022 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading dev...

The bloodbath for Cathie Wood’s ARK Innovation ETF (NYSEARCA:ARKK) continues, despite the fund being up slightly on Thursday. Wood’s ETF is -36% YTD and is currently working towards its fifth straight downward month. Meanwhile, this week has been particularly difficult...

The Ark Innovation ETF was fallen 60% from its high water mark, far more than 10%ish drop of the handful of growth stocks which top the S&P 500 and NASDAQ100. Charts and tables for price and AUM show clearly the the majority of investors in ARKK bought at the top; most ARKK holder...

MENLO PARK, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- PacBio , a leading provider of high-quality, highly accurate sequencing platforms, today announced it will be supporting The Hospital for Sick Children (SickKids) in Toronto, Canada in using HiFi whole genome sequencing (HiFi WGS) to...

The following slide deck was published by Pacific Biosciences of California, Inc. in conjunction with this event. For further details see: Pacific Biosciences of California (PACB) Presents At Global Healthcare Virtual Conference - Slideshow

MENLO PARK, Calif., Feb. 23, 2022 (GLOBE NEWSWIRE) -- PacBio (Nasdaq: PACB), a leading developer of high-quality, highly accurate sequencing platforms, welcomes Michael Eberle, Ph.D., as Vice President of Computational Biology. Michael will be responsible for leading the company’...

Cathie Wood reassured investors that innovation stocks are not in a bubble. Standing by her previous statement, "we are not in a bubble." In a CNBC interview, the asset manager reaffirmed her previous words, stating: "Absolutely. We stand by that." Wood, whose exchange traded funds ...

Pacific Biosciences (NASDAQ:PACB) has lost ~10% in the pre-market on Wednesday after several Wall Street analysts slashed their price targets on the life sciences company in reaction to its lower-than-expected earnings for Q4 2021. The company reported $36M in revenue for the quarte...